Jonathan Kimmelman

@KimmelmanJ

Bioethicist, Meta-scientist who studies drug development and risk

Vrijeme pridruživanja: kolovoz 2014.

Tweetovi

Blokirali ste korisnika/cu @KimmelmanJ

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @KimmelmanJ

  1. proslijedio/la je Tweet
    Odgovor korisniku/ci

    I don't disagree with you there, Jonathan! It is an oddity of the law that investors have stronger legal claims on information than research participants...

    Poništi
  2. ...it is a strange world we live in, that our legal system gives investors stronger claims on access to info about trial status than patients who volunteer their bodies. Brings to mind Marx's hyperbole about capitalism & vampires... END/

    Poništi
  3. Helpful and very clear argument from & about (under-recognized) problem of disclosure obligations to study volunteers when trials stop early. Just the same, 1/

    Poništi
  4. 4. velj

    Whatever happened to hi-dose chemo + hematopoietic SC xplant for treatment of stage III breast cancer? This 20-yr follow up of late '90s trial (still) shows no survival benefit. Kudos to researchers for the long term follow-up

    Poništi
  5. proslijedio/la je Tweet
    31. sij

    Save The Date: 19 Mar '20. Our next symposium will explore growing enthusiasms related to the use of psychedelics in psychiatric contexts and beyond. Co-sponsored by , Culture Mind & Brain Program, and the Division of Social and Transcultural Psychiatry

    Poništi
  6. 31. sij

    How is it that 'the analgesic effect of pregabalin was consistently robust across every etiology/measure tested, even for pain conditions that have not responded to pregabalin in patients?' New from newly minted PhD and

    Poništi
  7. proslijedio/la je Tweet
    29. sij

    “a country that tolerates evil means—evil manners, standards of ethics—for a generation, will be so poisoned that it never will have any good end.” in Sinclair Lewis, It Can't Happen Here Bequest of the author

    Poništi
  8. 29. sij

    Yes-right- MS trials are exactly one of the counterexamples I had in mind. Tons of drugs. High prices. But these are drugs where you take 1 until you fail, then go onto another until you fail, etc etc. So not huge competition...

    Poništi
  9. proslijedio/la je Tweet
    29. sij
    Odgovor korisnicima i sljedećem broju korisnika:
    Poništi
  10. 29. sij

    Yes- regression to the mean is part of it (also migration from sensitive surrogtes to specific clinical outcomes). See my article w/ in eLife

    Poništi
  11. 29. sij

    HT to and for fast response + evidence. Right... I had seen pub's like 's. I am not an economist so can't evaluate but the claim in was uncited and seemed tossed in like it was dogma.

    Poništi
  12. 29. sij

    Health economists: is there evidence for the following claim from ? "The more drugs there are in a particular therapeutic area, the more competitive is pricing." [my impression is that- w/ pharmaceuticals in USA it has not been the case].

    Poništi
  13. proslijedio/la je Tweet
    28. sij

    I argue that feminist intellectual & political efforts at combating oppression would be better served by focusing on reducing domination than they are by the current focus on relational autonomy

    Prikaži ovu nit
    Poništi
  14. 28. sij

    What happens after Polish clinical trials are completed? ~30% are not published within 5 years. That said, many Polish academic med centers do better than US peers, according to new study by (in collaboration w/ and colleagues)

    Poništi
  15. proslijedio/la je Tweet
    28. sij
    Odgovor korisnicima i sljedećem broju korisnika:
    Poništi
  16. 28. sij

    Deborah Zarin and Charles Pillar take on academic medical centres, , and lameness on trial results posting and enforcement

    Poništi
  17. proslijedio/la je Tweet
    27. sij
    Odgovor korisnicima

    That would certainly give new meaning to the annual SCT meeting.

    Poništi
  18. 26. sij

    But not to be confused with "Society of Clinical Trials."

    Poništi
  19. 24. sij

    Not the best week for . Was supposed to be in Cali for 2 talks- but wasn't (don't ask); then a project grant turfed; then work piled up. But better times ahead and these icicles on Mont Royal [photo] are pristine!

    Poništi
  20. 24. sij

    Appreciate ur sharing and we mid career and seniors needs to do a better job telegraphing this

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·